Skip to main content
Premium Trial:

Request an Annual Quote

Abbott s Pending Acquisition of Vysis Clears Antitrust Hurdles

NEW YORK, Nov. 23 - Abbott Laboratories' $355 million acquisition of Vysis came one step closer to closing on Friday as the Hart-Scott- Rodino Antitrust Improvements Act waiting period expired.


One month ago, Vysis agreed to be acquired by Abbott, which commenced a cash tender offer on Oct. 31 for all outstanding shares of the genomics-based disease management company for $30.50 per share, which represented a 33 percent premium. The tender offer is scheduled to expire on Nov. 29 but might have been stifled if the expiration period was extended.


Abbott, based in Abbott Park, Ill., set its sights on Vysis in the hopes of bolstering its position in the $800 million annual molecular diagnostics market.


Vysis is based in Downers Grove, Ill. It was not immediately clear when the companies hope to close the deal.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.